Interleukin-33 Drives Activation of Alveolar Macrophages and Airway Inflammation in a Mouse Model of Acute Exacerbation of Chronic Asthma

Table 1

Flow cytometric assessment of activation markers by AM.

Marker	Percentage of F4/80^+ AM staining positive		Mean fluorescence intensity (relative units)
	Naïve	Acute exacerbation	Naïve	Acute exacerbation
CD11b	3.43 ± 0.16	9.72 ± 1.62**	48.73 ± 5.27	95.53 ± 13.49**
CD11c	88.37 ± 1.06	92.05 ± 0.61*	81.97 ± 1.62	140.0 ± 4.93***
CD14	98.90 ± 0.12	98.17 ± 0.15	45.67 ± 0.68	190.8 ± 2.68***
CD16	98.18 ± 0.15	54.48 ± 1.70***	32.37 ± 0.82	19.97 ± 0.58***
CD23	4.31 ± 0.33	5.85 ± 0.14**	28.94 ± 0.31	28.38 ± 0.28
CD64	74.08 ± 1.74	62.77 ± 1.52**	15.93 ± 0.28	16.37 ± 0.37
CD80	81.83 ± 1.06	76.42 ± 0.58	17.12 ± 0.24	17.75 ± 0.17
CD86	61.35 ± 1.40	70.60 ± 1.92**	19.58 ± 0.21	29.83 ± 0.47***
MHCII	31.33 ± 1.62	55.93 ± 1.88***	171.8 ± 2.12	460.8 ± 22.34***

Data are mean ± SEM (𝑛=6 animals per group). Significant differences relative to naïve animals are shown as *(𝑃<0.05), **(𝑃<0.01), and ***(𝑃<0.001).